BEDFORD, Mass., Nov. 19, 2014 /PRNewswire/ — Hologic, Inc. (NASDAQ: HOLX), today announced the launch of the next-generation NovaSure 6mm global endometrial ablation (GEA) system. The NovaSure system is designed to apply radiofrequency energy to the endometrium and gently remove the lining of the uterus in two minutes or less. The new system offers customers a smaller diameter (6mm) ablation device and an advanced interactive touchscreen radiofrequency controller. The Company expects a full market release in both the domestic and international markets for the new NovaSure 6mm device in December 2014.
The NovaSure product enhancements are designed to improve patient comfort and physician ease-of-use while maintaining the clinical efficacy of the system. The new 6mm device requires less dilation and is designed to improve patient comfort – especially for patients under local anesthesia and/or paracervical block in-office. An advanced radiofrequency touchscreen controller provides physicians with procedural instructions on the controller interface along with an ablation timer and procedural summary screen.
The NovaSure system is used to treat women with abnormal uterine bleeding or heavy periods, a condition that affects one in five women 35-49 years old. NovaSure endometrial ablation is a one-time, five-minute procedure that can be done in the doctor’s office. To date over 2 million women have chosen the NovaSure procedure to treat the problem of lifestyle-restricting menstrual periods.
“Our next-generation NovaSure system provides feature enhancements that our customers have been requesting while maintaining the efficacy of the NovaSure ablation profile that has proven superior to other endometrial ablation modalities for over 10 years,” said Carter Houghton, Hologic’s Senior Vice President and General Manager, GYN Surgical Solutions. “NovaSure is the global market leader in endometrial ablation because it offers women a safe, effective and quick solution to excessive menstrual bleeding. The NovaSure procedure does not involve major surgery and allows women to return to their normal routines quickly, usually the next day. Additionally, the NovaSure procedure can result in health care savings, an important consideration in today’s economic environment.”
About the NovaSure System:
The NovaSure endometrial ablation system is a minimally invasive treatment for abnormal uterine bleeding (AUB). The system is designed to apply radiofrequency energy to the endometrium and gently remove the lining of the uterus in two minutes or less. The procedure requires no incisions, can be performed at any time during the menstrual cycle, and is often performed in an outpatient/office setting, providing flexibility to both the patient and physician. The NovaSure procedure typically allows patients to return to their normal activities the next day.
Unlike other endometrial ablation treatments, the NovaSure procedure is customized to each patient with a scientific endpoint and requires no hormonal pre-treatment, which is often associated with side-effects and treatment delays.
The NovaSure procedure provides a safe and effective alternative to hysterectomy or to less effective medical therapy for women suffering from excessive menstrual bleeding. With over 2 million procedures now performed, the NovaSure procedure is one of the most trusted and proven endometrial ablation modalities on the market. For more information, please visit www.novasure.com.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
Hologic, NovaSure and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s NovaSure system. There can be no assurance the product will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the product can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
SOURCE Hologic, Inc.